SSA
CRXT

Schonfeld Strategic Advisors’s Clarus Therapeutics Holdings, Inc. Common Stock CRXT Stock Holding History

Schonfeld Strategic Advisors’s Portfolio CRXT Stock Details CRXT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-20,800
Closed -$51K – 3109
2021
Q4 		$51K Buy
+20,800
New +$90.3K ﹤0.01% 1947
2021
Q3 		– Sell
-30,000
Closed -$302K – 2629
2021
Q2 		$302K Buy
30,000
+19,026
+173% +$192K ﹤0.01% 1470
2021
Q1 		$111K Buy
+10,974
New +$111K ﹤0.01% 1621

Other funds holding CRXT

BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Schonfeld Strategic Advisors's CRXT Position: Q1 2022 in Review

Schonfeld Strategic Advisors sold out of Clarus Therapeutics Holdings, Inc. Common Stock (CRXT) in Q1 2022, closing a stake of 20,800 shares — an estimated $51K sold.

Schonfeld Strategic Advisors first reported a position in CRXT in Q1 2021 and held it in 3 quarters. The position peaked at $302K in Q2 2021. 13 funds tracked by Wall St. Rank hold CRXT as of Q1 2022.

  • Schonfeld Strategic Advisors reported no remaining Clarus Therapeutics Holdings, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 20,800 Clarus Therapeutics Holdings, Inc. Common Stock shares in Q1 2022, an estimated $51K.
  • Schonfeld Strategic Advisors first reported a position in Clarus Therapeutics Holdings, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • Schonfeld Strategic Advisors's Clarus Therapeutics Holdings, Inc. Common Stock position peaked at $302K in Q2 2021.
  • 13 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Common Stock as of Q1 2022.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2022, filed 16 May 2022.